Chemo plus cetuximab after pembrolizumab for head and neck cancer
Part of Cancer clinical trials.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have squamous cell carcinoma of the head and neck (oral cavity, oropharynx, larynx, or hypopharynx) that has spread or come back and cannot be treated with surgery or radiation.
- You have already received pembrolizumab (with or without chemotherapy) as your first treatment, and your cancer has gotten worse. It has been at least 3 months since your last chemotherapy.
- You are physically well enough to be up and about (ECOG score 0, 1, or 2).
- You do not have active brain metastases, significant heart disease, or other serious uncontrolled health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before curative surgery can improve outcomes for people with resectable, recurrent head and neck squamous cell cancer. It also studies how these treatments affect the tumor and immune response using required tissue and blood samples.
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests adding a targeted therapy (cetuximab) to an immunotherapy (pembrolizumab or finotonlimab) plus chemotherapy for people with head and neck cancer that has spread or come back. The goal is to see if this combination works better than standard treatments.
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.